Last reviewed · How we verify
NCT05525650
Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients
Phase 1 trial testing House Dust Mite Extract, Dermatophagoides Farinae in Mite Allergy in 54 participants. Enrolling by invitation.
21 December 2024
Quick facts
| Lead sponsor | RAPHAS |
|---|---|
| Phase | Phase 1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 54 |
| Start date | 20 January 2022 |
| Primary completion | 21 December 2024 |
| Estimated completion | 15 June 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- House Dust Mite Extract, Dermatophagoides Farinae — full drug profile →
Conditions studied
- Mite Allergy — all drugs for Mite Allergy →
- Rhinitis, Allergic — all drugs for Rhinitis, Allergic →
- House Dust Mite Rhinitis — all drugs for House Dust Mite Rhinitis →
Sponsor
RAPHAS — full company profile →
Who can join
Adults 19 to 60, any sex, with Mite Allergy or Rhinitis, Allergic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
When administering clinical trial drugs to patients with house dust mite allergic rhinitis, safety/tolerance is comparatively evaluated as the primary outcome, and symptom improvement and immune activity of the disease are comparatively evaluated as secondary outcome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
From mechanism to applications: Advanced microneedles for clinical medicine.
Yang Y, Sun H, Sun X, Wang Y, et al · · 2025 · cited 9× · PMID 40463395 · DOI 10.1016/j.bioactmat.2025.04.025
Verify or expand the search:
- PubMed search for NCT05525650
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05525650 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RAPHAS
- Last refreshed: 10 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525650.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing